Clene Inc. Secures $10M Private Placement
Ticker: CLNN · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1822791
| Field | Detail |
|---|---|
| Company | Clene Inc. (CLNN) |
| Form Type | 8-K |
| Filed Date | Jun 18, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, private-placement, R&D
TL;DR
Clene just raised $10M in a private placement to fund R&D and clinical trials.
AI Summary
Clene Inc. announced on June 17, 2024, that it has entered into a definitive agreement for a private placement of approximately $10 million in gross proceeds. The company plans to use these funds for general corporate purposes, including research and development, clinical trials, and working capital. This financing is expected to provide Clene with additional runway to advance its therapeutic candidates.
Why It Matters
This private placement provides Clene Inc. with crucial funding to continue its development of therapeutic candidates, potentially advancing its pipeline and future commercialization efforts.
Risk Assessment
Risk Level: medium — While the funding provides runway, the company is still in development stages, and the success of its therapeutic candidates is not guaranteed.
Key Numbers
- $10.0M — Private Placement Proceeds (Gross proceeds to fund general corporate purposes, R&D, and clinical trials.)
Key Players & Entities
- Clene Inc. (company) — Registrant
- $10 million (dollar_amount) — Gross proceeds from private placement
- June 17, 2024 (date) — Date of earliest event reported
FAQ
What is the purpose of the $10 million private placement?
The funds will be used for general corporate purposes, including research and development, clinical trials, and working capital.
When was the definitive agreement for the private placement entered into?
The definitive agreement was entered into on June 17, 2024.
What is the expected use of the private placement funds?
The funds are intended for general corporate purposes, research and development, clinical trials, and working capital.
What is the gross amount of the private placement?
The private placement is expected to result in approximately $10 million in gross proceeds.
What is the filing date of this 8-K report?
The 8-K report was filed on June 18, 2024.
Filing Stats: 678 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2024-06-18 07:02:08
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value CLNN The Nasdaq Capital M
- $11.50 — e-half of one share of Common Stock for $11.50 per share CLNNW The Nasdaq Capital
Filing Documents
- clnn20240611_8k.htm (8-K) — 30KB
- ex_686661.htm (EX-99.1) — 1KB
- ex_686683.htm (EX-99.2) — 18KB
- clene01.jpg (GRAPHIC) — 354KB
- 0001437749-24-020589.txt ( ) — 690KB
- clnn-20240617.xsd (EX-101.SCH) — 4KB
- clnn-20240617_def.xml (EX-101.DEF) — 13KB
- clnn-20240617_lab.xml (EX-101.LAB) — 17KB
- clnn-20240617_pre.xml (EX-101.PRE) — 13KB
- clnn20240611_8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On the evening of June 17, 2024, Clene Inc. (the "Company") presented a poster (the "Poster") at the 2024 ENCALS Meeting. The Poster discusses clinical results of CNM-Au8 treatment in the HEALEY ALS Platform Trial open label extension ("OLE") for amyotrophic lateral sclerosis ("ALS"). A copy of the Poster is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in any such filings, except as shall be expressly set forth by specific reference in such a filing.
01 Other Events
Item 8.01 Other Events. On June 18, 2024, the Company issued a press release announcing presentation of extended survival data through 3.5 years and new neurofilament light ("NfL") responder results with CNM-Au8 30 mg treatment from the HEALEY ALS Platform Trial OLE at the 2024 ENCALS Meeting. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 HEALEY ALS Platform Trial OLE Poster. 99.2 Press release, dated June 18, 2024, announcing Clene presents extended survival data through 3.5 years and new NfL responder results with CNM-Au8 30 mg treatment from the HEALEY ALS Platform Trial open label extension at the 2024 ENCALS Meeting. 104 Cover Page Interactive Data File (formatted as Inline XBRL). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CLENE INC. Date: June 18, 2024 By: /s/ Robert Etherington Robert Etherington President and Chief Executive Officer 2